{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:05:18Z","timestamp":1774469118270,"version":"3.50.1"},"reference-count":24,"publisher":"Informa Healthcare","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2014,3,1]]},"DOI":"10.1185\/03007995.2013.858618","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T15:41:43Z","timestamp":1382629303000},"page":"493-508","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies"],"prefix":"10.1185","volume":"30","author":[{"given":"Anthony","family":"D\u2019Urzo","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto\rOntarioCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Kerwin","sequence":"additional","affiliation":[{"name":"Clinical Research Institute of Southern Oregon\rPC, Medford, ORUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[{"name":"Novartis Horsham Research Centre\rWest SussexUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation\rEast Hanover, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation\rEast Hanover, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Goyal","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG\rBaselSwitzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"key":"CIT0001","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD 2013). Global Strategy for Diagnosis, Management, and Prevention of COPD, 2013. Available at: http:\/\/www.goldcopd.org\/ [Last accessed 21 April 2013]"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2846"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1159\/000068417"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903103006"},{"key":"CIT0005","unstructured":"Higgins V, Broomfield S, Pollard R, Fermer S. Impact of morning symptoms on the working lives of COPD patients. Poster presented at COPD8 conference, 20\u201322 June 2012, Birmingham, UK"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.5.1294"},{"key":"CIT0007","unstructured":"European Medicines Agency (EMEA). Bretaris Genuair (aclidinium bromide) Summary of Product Characteristics. July 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002706\/WC500132732.pdf [Last accessed 22 November 2012]"},{"key":"CIT0008","unstructured":"European Medicines Agency (EMEA). Eklira Genuair (aclidinium bromide) Summary of Product Characteristics. July 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002211\/WC500132661.pdf [Last accessed 22 November 2012]"},{"key":"CIT0009","unstructured":"Food and Drug Administration (FDA). Tudorza Pressair (aclidinium bromide) US Prescribing Information. July 2012. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202450s000lbl.pdf [Last accessed 22 November 2012]"},{"key":"CIT0010","unstructured":"European Medicines Agency (EMEA). Seebri Breezhaler (glycopyrronium bromide) Summary of Product Characteristics. October 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002430\/WC500133769.pdf [Last accessed 22 November 2012]"},{"key":"CIT0011","unstructured":"Novartis Global. Media release: Novartis receives European Commission approval for once-daily Seebri\u00ae Breezhaler\u00ae as maintenance COPD treatment in the EU. October 2012. Available at: http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1645116.shtml [Last accessed 22 November 2012]"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-156"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040712"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200053377"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00068503a"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.09.011"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.90336.2008b"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S32451"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2011.615629"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00051110"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00269802"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00007"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008378"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2013.858618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T03:24:52Z","timestamp":1598757892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2013.858618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3,1]]}},"alternative-id":["10.1185\/03007995.2013.858618"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2013.858618","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2013-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}